Aims/hypothesis: Available multivariable equations for cardiovascular risk assessment in people with diabetes have been derived either from the general population or from populations with diabetes. Their utility and comparative performance in a contemporary group of patients with type 2 diabetes are not well established. The aim of this study was to evaluate the performance of the Framingham and UK Prospective Diabetes Study (UKPDS) risk equations in participants who took part in the Action in Diabetes and Vascular disease: Preterax and Diamicron-MR Controlled Evaluation (ADVANCE) trial.

Methods: The 4-year risks of cardiovascular disease (CVD) and its constituents were estimated using two published Framingham and the UKPDS risk equations in 7,502 individuals with type 2 diabetes without prior known CVD at their enrolment in the trial.

Results: The risk of major CVD was overestimated by 170% (95% CI 146-195%) and 202% (176-231%) using the two Framingham equations. The risk of major coronary heart disease was overestimated by 198% (162-238%) with the UKPDS, and by 146% (117-179%) and 289% (243-341%) with the two different Framingham equations, respectively. The risks of stroke events were also overestimated with the UKPDS and one of the Framingham equations. The ability of these equations to rank risk among ADVANCE participants was modest, with c-statistics ranging from 0.57 to 0.71. Results stratified by sex, treatment allocation and ethnicity were broadly similar.

Conclusions/interpretation: Application of the Framingham and UKPDS risk equations to a contemporary treated group of patients with established type 2 diabetes is likely to substantially overestimate cardiovascular risk.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00125-010-1681-4DOI Listing

Publication Analysis

Top Keywords

ukpds risk
16
risk equations
16
type diabetes
12
framingham equations
12
diabetes
10
risk
9
equations
9
framingham prospective
8
prospective diabetes
8
diabetes study
8

Similar Publications

Cost-effectiveness of fenofibrate for preventing diabetic complications in Australia.

Cost Eff Resour Alloc

November 2024

Abbott Products Operations AG, BASEL-LAND, Nathan, 4123, Switzerland.

Background: This study investigated the cost-effectiveness of using fenofibrate to treat type 2 diabetes in Australia. The financial burden of type 2 diabetes mellitus is estimated to surpass AUD10 billion, mainly due to the cost of diabetic complications from diabetic neuropathy. Clinical evidence from the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study demonstrated that fenofibrate can reduce the risk of amputation and other diabetes-related complications.

View Article and Find Full Text PDF

Using QALYs as an Outcome for Assessing Global Prediction Accuracy in Diabetes Simulation Models.

Med Decis Making

January 2025

Health Economics Research Centre, Nuffield Department of Population Health, University of Oxford, UK.

Objectives: (1) To demonstrate the use of quality-adjusted life-years (QALYs) as an outcome measure for comparing performance between simulation models and identifying the most accurate model for economic evaluation and health technology assessment. QALYs relate directly to decision making and combine mortality and diverse clinical events into a single measure using evidence-based weights that reflect population preferences. (2) To explore the usefulness of Q, the proportional reduction in error, as a model performance metric and compare it with other metrics: mean squared error (MSE), mean absolute error, bias (mean residual), and .

View Article and Find Full Text PDF

Younger-onset compared with later-onset type 2 diabetes: an analysis of the UK Prospective Diabetes Study (UKPDS) with up to 30 years of follow-up (UKPDS 92).

Lancet Diabetes Endocrinol

December 2024

Diabetes Trials Unit, Oxford Centre for Diabetes, Endocrinology and Metabolism, Radcliffe Department of Medicine, University of Oxford, Oxford, UK. Electronic address:

Background: Younger-onset type 2 diabetes is associated with accelerated complications. We assessed whether complications and mortality rates differed for younger age compared with older age at diagnosis over 30 years of follow-up.

Methods: In this study, we used data from the UKPDS, collected between 1977 and 2007, of participants aged 25-65 years with newly diagnosed type 2 diabetes with younger-onset (younger than 40 years) or later-onset (40 years or older), and without diabetes autoantibodies.

View Article and Find Full Text PDF
Article Synopsis
  • Most current risk equations for predicting diabetic kidney disease (DKD) are based on outdated data from mostly Caucasian populations, prompting the need to adapt these models using real-world data from Taiwanese type 2 diabetes (T2D) patients.
  • The study evaluated three simulation models (UKPDS-OM2, RECODe, and CHIME) for their ability to predict DKD progression, with results indicating that while some showed moderate discrimination, they often underestimated or overestimated risks.
  • After recalibrating the equations, the updated RECODe for micro- and macroalbuminuria and the CHIME for renal failure exhibited improved predictions, making them suitable for use in a multi-state
View Article and Find Full Text PDF

Objective: To adapt risk prediction equations for myocardial infarction (MI), stroke, and heart failure (HF) among patients with type 2 diabetes in real-world settings using cross-institutional electronic health records (EHRs) in Taiwan.

Methods: The EHRs from two medical centers, National Cheng Kung University Hospital (NCKUH; 11,740 patients) and National Taiwan University Hospital (NTUH; 20,313 patients), were analyzed using the common data model approach. Risk equations for MI, stroke, and HF from UKPDS-OM2, RECODe, and CHIME models were adapted for external validation and recalibration.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!